Tenon Medical Inc. Common Stock Q3 2025 Earnings Recap

TNON Q3 2025 November 14, 2025

Tenon Medical demonstrated robust growth in Q3 2025, achieving record revenues of $1.2 million, a 32% increase year-over-year, driven by high demand for its innovative sacroiliac joint fusion solutions.

Earnings Per Share Miss

$-0.40 vs $-0.36 est.

-11.1% surprise

Revenue Miss

1173000 vs 1378500 est.

-14.9% surprise

Market Reaction

1-Day +0.0%

5-Day -5.93%

30-Day -5.93%

Key Takeaways

Successful integration of CyVantage's Symmetry portfolio contributed to top-line growth, marking a pivotal point in Tenon’s strategic expansion.
Full commercial launch of the Catamaran SE system showcased enhanced functionality, addressing varied patient needs and improving competitive positioning.
Positive clinical outcomes from the ongoing main sales study further validated the efficacy of the Catamaran system, with statistically significant improvements in patient pain and disability scores.
Tenon received FDA 510(k) clearance for the Symmetry Plus system, enhancing its product offerings and preparing for the upcoming alpha launch.
Cash position remained strong at $3.4 million with no debt, supplemented by a recent $2.85 million investment.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TNON on AllInvestView.